Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXG0HS
|
||||
| Drug Name |
1-[3-(4-Methyl-piperazin-1-yl)-propyl]-4-(3-phenyl-pyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyridin-2-one
|
||||
| Synonyms |
CHEMBL116324
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C25H28N6O
|
||||
| Canonical SMILES |
CN1CCN(CCCN2C=CC(=CC2=O)c3cnc4c(cnn4c3)c5ccccc5)CC1
|
||||
| InChI |
InChI=1S/C25H28N6O/c1-28-12-14-29(15-13-28)9-5-10-30-11-8-21(16-24(30)32)22-17-26-25-23(18-27-31(25)19-22)20-6-3-2-4-7-20/h2-4,6-8,11,16-19H,5,9-10,12-15H2,1H3
|
||||
| InChIKey |
RBXCUPOYMILATN-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.